|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2505-2515.
 Previous Article | Table of Contents | Next Article 
ASH 50TH ANNIVERSARY REVIEW
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang1, and
Zhu Chen1,2
1 Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Rui Jin Hospital affiliated to the Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai; and
2 Shanghai Center for Systems Biomedicine at SJTU, Shanghai, China
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia. Morphologically, it is identified as the M3 subtype of acute myeloid leukemia by the French-American-British classification and cytogenetically is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion between promyelocytic leukemia (PML) gene and retinoic acid receptor  (RAR). It seems that the disease is the most malignant form of acute leukemia with a severe bleeding tendency and a fatal course of only weeks. Chemotherapy (CT; daunorubicin, idarubicin and cytosine arabinoside) was the front-line treatment of APL with a complete remission (CR) rate of 75% to 80% in newly diagnosed patients. Despite all these progresses, the median duration of remission ranged from 11 to 25 months and only 35% to 45% of the patients could be cured by CT. Since the introduction of all-trans retinoic acid (ATRA) in the treatment and optimization of the ATRA-based regimens, the CR rate was raised up to 90% to 95% and 5-year disease free survival (DFS) to 74%. The use of arsenic trioxide (ATO) since early 1990s further improved the clinical outcome of refractory or relapsed as well as newly diagnosed APL. In this article, we review the history of introduction of ATRA and ATO into clinical use and the mechanistic studies in understanding this model of cancer targeted therapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al.
Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience
J. Clin. Oncol.,
June 1, 2009;
27(16):
2668 - 2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. He and Q. Ma
Induction of Metallothionein I by Arsenic via Metal-activated Transcription Factor 1: CRITICAL ROLE OF C-TERMINAL CYSTEINE RESIDUES IN ARSENIC SENSING
J. Biol. Chem.,
May 8, 2009;
284(19):
12609 - 12621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Nowak, D. Stewart, and H. P. Koeffler
Differentiation therapy of leukemia: 3 decades of development
Blood,
April 16, 2009;
113(16):
3655 - 3665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Pendino, E. Nguyen, I. Jonassen, B. Dysvik, A. Azouz, M. Lanotte, E. Segal-Bendirdjian, and J. R. Lillehaug
Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis
Blood,
April 2, 2009;
113(14):
3172 - 3181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q.-Y. Zhang, J.-H. Mao, P. Liu, Q.-H. Huang, J. Lu, Y.-Y. Xie, L. Weng, Y. Zhang, Q. Chen, S.-J. Chen, et al.
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia
PNAS,
March 3, 2009;
106(9):
3378 - 3383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hu, Y.-F. Liu, C.-F. Wu, F. Xu, Z.-X. Shen, Y.-M. Zhu, J.-M. Li, W. Tang, W.-L. Zhao, W. Wu, et al.
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
PNAS,
March 3, 2009;
106(9):
3342 - 3347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, E. Estey, D. Jones, S. Faderl, S. O'Brien, J. Fiorentino, S. Pierce, D. Blamble, Z. Estrov, W. Wierda, et al.
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
J. Clin. Oncol.,
February 1, 2009;
27(4):
504 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gianni', A. Boldetti, V. Guarnaccia, A. Rambaldi, E. Parrella, I. Raska Jr., C. Rochette-Egly, G. Del Sal, A. Rustighi, M. Terao, et al.
Inhibition of the Peptidyl-Prolyl-Isomerase Pin1 Enhances the Responses of Acute Myeloid Leukemia Cells to Retinoic Acid via Stabilization of RAR{alpha} and PML-RAR{alpha}
Cancer Res.,
February 1, 2009;
69(3):
1016 - 1026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hosiner, H. Lempiainen, W. Reiter, J. Urban, R. Loewith, G. Ammerer, R. Schweyen, D. Shore, and C. Schuller
Arsenic Toxicity to Saccharomyces cerevisiae Is a Consequence of Inhibition of the TORC1 Kinase Combined with a Chronic Stress Response
Mol. Biol. Cell,
February 1, 2009;
20(3):
1048 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saumet, G. Vetter, M. Bouttier, E. Portales-Casamar, W. W. Wasserman, T. Maurin, B. Mari, P. Barbry, L. Vallar, E. Friederich, et al.
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia
Blood,
January 8, 2009;
113(2):
412 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Rowley
Chromosomal translocations: revisited yet again
Blood,
September 15, 2008;
112(6):
2183 - 2189.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frohling and H. Dohner
Chromosomal Abnormalities in Cancer
N. Engl. J. Med.,
August 14, 2008;
359(7):
722 - 734.
[Full Text]
[PDF]
|
|
|
|
|
